Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome. The discussion centered on diverse treatment strategies for myelodysplastic ...

TURKU, FI / ACCESS Newswire / February 23, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunotherapies ...

The expert panel looks to future treatment management for patients with myelodysplastic syndrome. Ryan Haumschild, PharmD, MS, MBA: I want to think about the future. How is the future changing? Dr ...

Hypomethylating agents are standard in MDS treatment, with new drugs like Rytelo enhancing anemia management. Targeted therapies for IDH1/IDH2 mutations offer promising options, though challenges in ...

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global myelodysplastic syndrome treatment market was valued at US$ 2,324.8 million in 2018, and is expected to exhibit a CAGR of ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We all know that MDS is a cancer of the ...

Dr. Shah was compensated by BMS for his participation. Photo Credit: Shutterstock As you age, feeling tired or short of breath may be dismissed as a part of getting older, but it’s important to talk ...

Please provide your email address to receive an email when new articles are posted on . Most patients with newly diagnosed high-risk myelodysplastic syndrome do not receive guideline-recommended ...

Geron is planning to submit a New Drug Application (NDA) for imetelstat, a treatment for low to intermediate-1 risk myelodysplastic syndromes (MDS), in 2023 after favorable Phase 3 trial results.

Social worker Marie Brewer talks about the challenges of supporting a loved one with myelodysplastic syndrome (MDS) and ways to find assistance and treatment options. Myelodysplastic syndromes (MDS) ...

For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs). Borate notes that despite their continued use, there has been limited ...